Abstract B102: A phase 2, open-label study of the PARP inhibitor rucaparib in patients with pancreatic cancer and a known deleterious BRCA mutation
Susan M. Domchek(University City Science Center), Robert H. Vonderheide(University of Pennsylvania), Mitch Raponi(Clovis Oncology (United States)), Heidi Giordano(Mayo Clinic in Arizona), Steven R. Alberts(North Central Cancer Treatment Group), Andrew Hendifar(Cedars-Sinai Medical Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), George Kim(Nemours Children’s Clinic), Ravit Geva(Tel Aviv Sourasky Medical Center), Andrew R. Allen(Vanderbilt University), Ron Epelbaum(University of Bern), Andrew V. Biankin(University of Glasgow), Lawrence Leichman(New York University), Lindsey Rolfe, Robert R. McWilliams(Mayo Clinic in Arizona), Jeff Isaacson(Clovis Oncology (United States)), Rachna T. Shroff(University of Arizona)
Cited by 4
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k